
Sequencing Strategies for Limited-Volume Metastatic RCC
A second patient case explores treatment selection and sequencing in metastatic RCC with limited disease burden.
Episodes in this series

A second patient case explores treatment selection and sequencing in metastatic RCC with limited disease burden. The patient is an otherwise healthy woman with several lung metastases not amenable to surgery or radiation. Faculty explain how age, performance status, comorbidities, and risk group guide the choice. Dual immunotherapy suits patients pursuing a deep, durable response, while an immunotherapy-TKI regimen may suit favorable-risk disease. For progression after dual immunotherapy, the panel weighs belzutifan plus lenvatinib against single-agent cabozantinib or tivozanib. Hypoxia-inducible factor inhibition requires reliable patients who can check oxygen saturation at home and get timely laboratory monitoring for anemia, which can be hard for those living far from specialty care. The panel also questions the practice of saving active therapies for later lines. Faculty cite longstanding evidence of substantial attrition between successive lines and argue that frontline decisions should prioritize what is best for the patient now.
Related to this article








